Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07307300

Study on Risk Assessment for Patients With Microscopic Hematuria (Non-Visible Blood in Urine) Using a Urine Marker Test

Risk Stratification of Patients With Non-Visible Hematuria - A Prospective Validation Study Using a Urine Marker-Based Assessment (Xpert® Bladder Cancer Detect)

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
1,475 (estimated)
Sponsor
Christian Bolenz · Academic / Other
Sex
All
Age
40 Years
Healthy volunteers
Not accepted

Summary

The goal of this clinical study is to learn how well a urine test called Xpert® Bladder Cancer Detect (Xpert BC-D) can help doctors assess the risk of bladder cancer in people with non-visible blood in their urine (microscopic hematuria). The main questions it aims to answer are: * Can the Xpert BC-D test accurately identify people at higher risk for bladder cancer? * Can combining the test results with other clinical information improve risk assessment compared to standard evaluation methods? Participants will: * Have leftover urine from the routine initial evaluation tested with the Xpert® Bladder Cancer Detect assay * Complete questionnaires about urinary symptoms using the modified IPSS and ICIQ-FLUT-S forms * Attend a first visit for medical evaluation and cystoscopy * Attend a follow-up visit 3 to 6 months later for additional testing and questionnaires This study includes adults over 40 years of age who have had microscopic hematuria detected within the past six months. People with a history of bladder cancer, urinary tract surgery, or certain other medical conditions, as well as individuals who are currently pregnant, cannot participate. The study will be conducted at 20-24 sites in Germany and Austria and will last approximately 27 months, with each participant involved for about 6 months. The results of this study may help doctors better decide which patients need further invasive testing, potentially reducing unnecessary procedures.

Conditions

Timeline

Start date
2026-03-01
Primary completion
2028-06-01
Completion
2028-06-01
First posted
2025-12-29
Last updated
2025-12-29

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT07307300. Inclusion in this directory is not an endorsement.